Last reviewed · How we verify

NCT06368349

Persistent Lymphopenia in Liver Transplantation and Its Molecular Insights for Hepatocellular Carcinoma

Completed Last updated 18 April 2024
What this trial tests

trial in Lymphopenia in 190 participants. Completed in 30 June 2023.

Timeline
1 March 2022
Primary endpoint
21 June 2023
30 June 2023

Quick facts

Lead sponsorChang Gung Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment190
Start date1 March 2022
Primary completion21 June 2023
Estimated completion30 June 2023
Sites1 location across Taiwan

Conditions studied

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 20 to 80, any sex, with Lymphopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 145 Liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) were retrospectively enrolled at Kaohsiung Chang Gung Memorial Hospital between 2006 and 2019. Clinical records from 7 days before LT (pre-LT) to 1 year after LT (post-LT) were analysed. In a prospective study from March 2022 to June 2023, 20 lymphopenia and 25 non-lymphopenia HCC recipients were enrolled, and a phenotypic analysis of peripheral blood lymphocytes was performed using multiparameter flow cytometry.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lymphopenia

Currently open trials in the same condition.

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06368349.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing